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ABSTRACT
Introduction: Intravenous medication is essential for
many hospital inpatients. However, providing
intravenous therapy is complex and errors are
common. ‘Smart pumps’ incorporating dose error
reduction software have been widely advocated to
reduce error. However, little is known about their effect
on patient safety, how they are used or their likely
impact. This study will explore the landscape of
intravenous medication infusion practices and errors in
English hospitals and how smart pumps may relate to
the prevalence of medication administration errors.
Methods and analysis: This is a mixed-methods
study involving an observational quantitative point
prevalence study to determine the frequency and types
of errors that occur in the infusion of intravenous
medication, and qualitative interviews with hospital
staff to better understand infusion practices and the
contexts in which errors occur. The study will involve 5
clinical areas (critical care, general medicine, general
surgery, paediatrics and oncology), across 14
purposively sampled acute hospitals and 2 paediatric
hospitals to cover a range of intravenous infusion
practices. Data collectors will compare each infusion
running at the time of data collection against the
patient’s medication orders to identify any
discrepancies. The potential clinical importance of
errors will be assessed. Quantitative data will be
analysed descriptively; interviews will be analysed
using thematic analysis.
Ethics and dissemination: Ethical approval has
been obtained from an NHS Research Ethics
Committee (14/SC/0290); local approvals will be
sought from each participating organisation. Findings
will be published in peer-reviewed journals and
presented at conferences for academic and health
professional audiences. Results will also be fed back to
participating organisations to inform local policy,
training and procurement. Aggregated findings will
inform the debate on costs and benefits of the NHS
investing in smart pump technology, and what other
changes may need to be made to ensure effectiveness
of such an investment.
BACKGROUND
Safety of intravenous medication
administration
Intravenous medication is essential for many
hospital inpatients. However, providing intra-
venous therapy is complex, and errors in the
administration of intravenous medication are
common. In a systematic review of UK
studies using structured observation of medi-
cation administration, errors were ﬁve times
more likely in intravenous than non-
intravenous doses.1 Published error rates vary
from 18% to 173% of intravenous doses
given.2 An international systematic review
estimated the probability of making at least
one error in the preparation and administra-
tion of a dose of intravenous medication to
be 0.73, with most errors occurring at the
reconstitution and administration steps.3
While many of these errors do not result in
patient harm, all can cause anxiety for staff
and patients, and reduce patients’ conﬁ-
dence in their care. As a result, the
Strengths and limitations of this study
▪ Intravenous medication errors are common and
efforts are required to reduce their occurrence.
Little is known about practices and how they
relate to the prevalence of error in England.
▪ Smart infusion pumps are beginning to be
adopted, but their potential impact on the preva-
lence of error needs to be assessed.
▪ A mixed-methods (quantitative and qualitative)
observational study will investigate different
intravenous practices and how they relate to
prevalence of errors.
▪ The study is limited to medication administration
errors. It does not include prescription errors or
evaluate the clinical appropriateness of what is
prescribed.
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administration of intravenous medication has been iden-
tiﬁed as a signiﬁcant topic of concern by regulators,
manufacturers and healthcare providers.4
The potential role of smart infusion pumps
To reduce errors associated with intravenous infusions,
‘smart pumps’ incorporating dose error reduction soft-
ware have been widely advocated.5–7 This software checks
programmed infusion rates against preset limits for each
drug and clinical location, using customisable ‘drug librar-
ies’, to reduce the risk of infusion rates that are too high
or too low. Limits may be ‘soft’ (in which case they can be
over-ridden following conﬁrmation by the clinician) or
‘hard’ (in which case they cannot). Smart pumps may be
stand-alone or integrated with electronic prescribing and/
or barcode administration systems, and usually allow
administrative data such as number and types of over-rides
to be downloaded for analysis. While smart pumps were in
use in 68% of US hospitals in 2011,8 their use is not yet as
widespread in the UK.9 Such technology can potentially
identify and prevent some kinds of medication errors but
cannot prevent all possible errors. Smart pump use also
comes at a cost, both ﬁnancial and in terms of changes to
practice needed to make their use effective. For instance,
Husch et al10 carried out a hospital-wide point prevalence
study of errors in intravenous infusions using standard
infusion pumps and identiﬁed infusion rate errors in 37
cases (8% of all infusions), and wrong medication in 14
cases (3%). However, they estimated that only one of these
errors would have been prevented using stand-alone smart
pumps. More were judged to be potentially preventable if
the pumps were integrated with other hospital systems,
such as electronic prescribing and barcode-assisted
administration.
A recent systematic review identiﬁed 21 quantitative
studies of smart pumps,11 the majority of which studied
the over-rides recorded in the smart pump logs and/or
used unreliable methods of identifying medication
errors and adverse drug events such as incident reports.
The authors concluded that smart pumps can reduce
but not eliminate error, and that the picture was far
from conclusive. Furthermore, most studies were con-
ducted in the USA, none was from the UK where
systems for prescribing and administering medication
differ from those in the USA.12 For example, nurses play
a more active role in preparing intravenous medication
in the UK, and all medication orders have to be in
writing. We therefore know little about the effect on
patient safety of using smart pumps in general and
nothing about their likely impact in the UK.
Methodological approach
To supplement a quantitative description of the preva-
lence, types and clinical importance of errors, qualitative
methods help to understand why errors occur and why
technologies designed to deliver safer practices do not
always do so. Interviews and observational methods can
also shed light on the complex and varied situations
within which infusion devices are used across clinical con-
texts and hospitals.13 14 Studies have found that infusion
practices vary signiﬁcantly between and within hospitals.
For example, in a series of observational studies, nurses in
an oncology day care unit were found to follow fairly basic
procedures in setting up planned infusions,15 whereas
nurses in an intensive care unit routinely used advanced
functionality, frequently setting up several pumps in paral-
lel to deliver different medications.16 There is an increas-
ing drive towards standardising devices within institutions,
intended to reduce potential risks associated with staff
using a range of different devices or devices conﬁgured in
different ways, or being required to operate devices that
they are not familiar with or have not been trained to use.
However, not all clinical areas require the same functional-
ity—for example, Carayon et al17 studied how nurses use
infusion devices in different areas of the hospital. They
compared the tasks actually carried out with the tasks as
deﬁned by ward protocol. They identiﬁed divergences in
practice and highlighted ways in which these divergences
increased overall system vulnerability.
Few previous studies have brought together the per-
spectives of quantitative observational studies with quali-
tative interviews and observations. Furthermore, this
multidisciplinary project combines clinical and human
factors research perspectives. Our approach is to deliver
overview and detail of intravenous medication infusion
practices and identify the roles of different infusion
technologies and practices in minimising the risks of
medication administration errors.
METHODS AND ANALYSIS
Aim and objectives
The Exploring the Current Landscape of Intravenous
Infusion Practices and Errors (ECLIPSE) study is a multi-
phase project, the aims of which are to describe how intra-
venous medication is infused in English hospitals, how
often and why errors occur and the likely impact of smart
pump technology on patient safety (table 1).
1. This protocol relates to the ﬁrst phase, which will com-
prise a point prevalence study of intravenous infusion
administration and qualitative focus groups and inter-
views with key hospital staff. Subsequent phases will
comprise in-depth observational studies from a human
factors perspective, to situate the ﬁndings of the ﬁrst
phase within a broader context, and a synthesis of the
ﬁndings to make recommendations for safer adminis-
tration of intravenous medication. Objectives of the
ﬁrst phase are to document the prevalence, types and
clinical importance of errors involving the infusion of
intravenous medication in a sample of English hospi-
tals, and compare ﬁndings with data from a US study.
2. Explore potential sources of variation in the rates,
types and clinical importance of errors in relation to
mode of infusion delivery (gravity administration,
standard infusion pumps and syringe drivers, and
smart infusion pumps and syringe drivers) and
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clinical area (critical care, general surgery, general
medicine, paediatrics and oncology).
3. Explore staff perspectives on potential explanatory
factors behind the ﬁndings.
4. Describe, based on interviews with hospital staff, how
intravenous infusions are administered in a sample of
English hospitals, focusing on differences in prac-
tices, equipment, policies and processes, within and
between hospitals.
Study design
The study will employ a mixed-methods approach bring-
ing together complementary quantitative and qualitative
methods to address these objectives. A quantitative point
prevalence study, using observational methods, will be
used to document the prevalence, types and clinical
importance of errors associated with the infusion of intra-
venous medication. Qualitative focus groups and inter-
views with relevant hospital staff will help explain the
ﬁndings.18 The design of the point prevalence study is
based closely on that used in a similar US multicentre
study which studied general medical, general
surgical, medical intensive care and surgical intensive
care units (K Schnock and DW Bates, personal communi-
cation, 2013). This approach, originally developed
by Husch et al,10 involves trained staff systematically
comparing details of each intravenous infusion in
progress at the time of observation with the medication
prescribed, to identify any discrepancies. Within
ECLIPSE, once quantitative data have been analysed,
interviews with key staff will also be conducted to reﬂect
on the point prevalence results and details of hospital
intravenous practices.
Study setting, recruitment and sample selection
The study will take place within acute hospitals across
England. Expressions of interest were sought from
English National Health Service (NHS) hospital trusts
through the National Institute for Health Research
(NIHR) Clinical Research Network, the UK National
Association of Medical Device Educators and Trainers
(NAMDET) and contacts from a previous study.9
Interested parties were then invited to complete an
online survey to provide an overview of their hospital,
capacity to take part, infusion pumps and practices.
Eighteen NHS trusts responded to the survey, providing
information about 26 potential hospital sites. We are
inviting 14 acute hospitals and 2 specialist children’s hos-
pitals to take part in the ﬁrst phase of ECLIPSE.
Hospitals are being chosen purposively, with the aim of
representing maximum variation in terms of type, size,
geographic location, potential indicators of patient
safety such as being a Bruce Keogh Trust,19 hospital
mortality indexes20 and media reports, and their self-
reported use of infusion devices and smart pump tech-
nology. We aim to include a mixture of hospitals that
use smart pumps with dose error reduction software,
and those who do not. If any particular gaps are identi-
ﬁed, additional hospital sites will be approached to
ensure a wide range of practices are included.
In each participating hospital, we will study a
minimum of three clinical areas (critical care, general
medicine and general surgery). This set has been
chosen to represent a range of clinical areas while also
mirroring as closely as possible the US study, recognising
that UK hospitals do not typically have separate medical
and surgical intensive care units. However, in contrast to
the US study, we will also include paediatric and oncol-
ogy, since these are areas where, at least anecdotally, dif-
ferent types of errors may be more likely to occur and/
or have greater consequences. In each hospital, each
clinical area may include just one, or more than one,
individual ward as needed.
We aim to include observation of 2100 infusions in
total across all study sites. Using nQuery Advisor
(Statistical Solutions, V.7.0), this sample will give a CI
around a 10% overall error rate across hospitals and clin-
ical areas of 8.7–11.3%.7 10
Definitions
Medication infusions will be taken to include any medica-
tion, ﬂuids, blood products and nutrition administered
via intravenous infusion, including patient-controlled
analgesia.
A medication administration error will be considered
to be any deviation in the administration of an intraven-
ous infusion from a doctor’s written medication order,
the hospital’s intravenous policy and guidelines, or the
manufacturer’s instructions. This will be taken to
include the administration of medication to which the
patient had a documented allergy or sensitivity; other
aspects of the clinical appropriateness of the medication
order and its administration will not be assessed. We will
Table 1 The three different phases of the ECLIPSE study
1 Point prevalence study and follow-up focus groups
and interviews in 16 hospital sites
▸ Quantitative observational study of intravenous administration
▸ In-depth discussions with key staff at participating sites to
understand practices
2 In-depth observational study in a subset of these sites More detailed ethnographic study of a subset of sites to better
understand detailed practices
3 Recommendations and summary reporting Dialogue with participating hospitals to jointly identify and
communicate recommendations for best practice
ECLIPSE, Exploring the Current Landscape of Intravenous Infusion Practices and Errors.
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also collect data on other procedural or documentation
discrepancies which do not meet the deﬁnition of a
medication administration error but which may increase
the likelihood of administration errors occurring. These
will include patients not wearing an identiﬁcation wrist-
band with the correct information, tubing not being
tagged and labelled in accordance with local policy, and
failure to document the administration of the medica-
tion in line with hospital policy. Deﬁnitions of error and
discrepancy types are given in table 2.
Data collection
Point prevalence study
At each study site, these data will be collected by two
clinicians who are employees of the participating site,
usually a nurse and a pharmacist or experienced phar-
macy technician, following training by the research
team. The training will include the study protocol, data
collection and documentation procedures.
Data will be collected on 1 day or an equivalent period
in each clinical area. On selected observation days, the
local data collectors will move systematically around each
ward, gathering data from each patient with an infusion
running. The aim will be to gather data from every infu-
sion that is being administered at that time. Wards will
be selected with the aim of gathering data from 30 to 40
infusions from each clinical area in each hospital. The
data collectors will compare the medication being admi-
nistered against the patient’s prescribed medication and
relevant medication administration records to identify
any discrepancies. This will include a comparison of the
medication or ﬂuid name, the concentration and rate of
infusion. Relevant data such as patient allergies, pump
type and any procedural or documentation errors will
also be recorded. Where it appears that one discrepancy
has been introduced to compensate for another discrep-
ancy, data gatherers are being trained to note this. Data
collectors are also expected to have familiarised them-
selves with their hospital’s policies and to check guide-
lines and manufacturers’ instructions for themselves
when in doubt. The two observers will work together,
each checking the data collected with the other and
agreeing whether or not any medication administration
error or other discrepancy has been identiﬁed. Multiple
errors and discrepancies may be identiﬁed for a single
infusion.
Table 2 Definitions of error and discrepancy types
Discrepancy/error type Definition
Medication administration errors
Unauthorised medication/fluids (no
documented order)
Fluids/medications are being administered but no medication order is present. This
includes failure to document a verbal order if these are permitted as per hospital
policy.
Wrong medication or fluid A different fluid/medication/diluent as documented on the intravenous bag (or
bottle/syringe/other container) is being infused compared with that specified on the
medication order or in local guidance.
Concentration discrepancy An amount of a medication in a unit of solution that is different from that
prescribed.
Dose discrepancy The same medication but the total dose is different from that prescribed.
Rate discrepancy A different rate is being delivered from that prescribed. Also refers to weight-based
rates calculated incorrectly including using a different patient weight from that
recorded on the patient’s chart.
Delay of dose or medication/fluid
change
An order to change the medication or rate not carried out within 4 h of the written
medication order, or as per local policy.
Omitted medication or intravenous
fluids
The medication prescribed was not administered.
Allergy oversight Medication is prescribed/administered despite the patient having a documented
allergy or sensitivity to the drug concerned.
Expired drug The expiry date/time on either the manufacturer’s or additive label has been
exceeded.
Roller clamp discrepancy The roller clamp is not positioned appropriately/correctly.
Procedural and documentation discrepancies
Patient identification error Patient either has no identification (ID) band on wrist, or information on their ID
band is incorrect.
Wrong or missing information on
additive label
Any incorrect or missing information on the additive label, as required by hospital
policy
Tubing not tagged according to policy Tagging or labelling of tubing is different (either missing or incorrect) from
requirements in hospital policy.
Documentation error Medication/fluids administered but not documented correctly on chart, eg, missing
signature, start time, etc.
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Contextual interviews
Once data from the point prevalence study have been
analysed, we will liaise with key staff in participating hos-
pitals to share our ﬁndings and explore potential
explanatory factors behind those ﬁndings (eg, nursing
practices, equipment, policies and processes, staff man-
agement, training and competency assessment). This
will involve a two-way dialogue with relevant members of
staff including ward managers, senior nursing staff,
patient safety specialists, medical electronics personnel,
trainers, those with responsibility for procurement, and
senior managers. We will invite a purposive sample of
these staff (typically 3–5 per hospital) to participate in
individual or group semistructured qualitative interviews,
aiming for maximum variation in staff roles and respon-
sibilities. The interview will focus on the participant’s
views of local policy and practice, what works well and
less well, and what changes are under consideration.
They will be used to clarify any queries from the observa-
tional data and will focus primarily on normal practice
rather than extreme events. If there appear to be incon-
sistencies between the ways that data gathering has been
done across sites (despite consistent training), this will
also be explored during interviews and data will be
adjusted if deemed necessary to improve consistency
across sites. Subject to participants giving consent, inter-
views will be recorded and professionally transcribed.
Data management and analysis
Point prevalence study
Data will be either recorded on a standardised paper
form (ﬁgure 1) and subsequently uploaded to a secure
web-based REDCap data collection tool21 or entered dir-
ectly into REDCap, depending on which better ﬁts local
practices. No patient-identiﬁable data will be entered.
The data collection forms and online database have
been adapted from that used in the USA and piloted to
ensure they are applicable and relevant in the UK hos-
pital context. Each site will be able to access their own
data, while the central research team will be able to
access data across all sites.
We will use two methods to assess the clinical importance
of each discrepancy or error identiﬁed. First, these will be
classiﬁed according to an adapted version of the US
National Coordinating Council for Medication Error
Reporting and Prevention (NCC MERP) index for categor-
ising medication errors. The adaptation allows for the
assigned severity ratings to be based on the likelihood of
the error to have resulted in patient harm if it had not
been intercepted, rather than actual patient harm for
which the NCC MERP index was originally designed
(tables 3 and 4). Our adapted version of NCC MERP also
includes the term ‘discrepancy’ to capture minor devia-
tions in practice where observers feel the deviation is not
necessarily wrong and does not fall into our deﬁnition of a
medication administration error. The second is separating
category A into A1 and A2 so that more minor discrepan-
cies can be better characterised. Guidance will be provided
to data collectors on how to categorise deviations and
errors, including illustrative examples. Where there are
factors that make initial categorisation difﬁcult, ﬁnal assign-
ment of clinical importance will be determined by consen-
sus among the research team and local data collectors.
Second, we will use an established method for assessing
the severity of medication administration errors, devel-
oped and validated in the UK,22 which involves four
experienced healthcare professionals, each assessing
each error on a scale of 0–10, where 0 represents an error
with no potential consequences to the patient and 10 an
error which would result in death. The mean score across
the four judges is then used as an index of severity which
has been shown to be reliable and valid. Use of the two
different methods for assessing clinical importance will
allow us to compare the classiﬁcations obtained using
NCC MERP with the scores obtained using the more
time-consuming but potentially more robust second
method. Using the adapted NCC MERP index will also
permit comparison with the US study ﬁndings.
Descriptive statistics will be used to calculate overall medi-
cation administration error and discrepancy rates in rela-
tion to hospital site, clinical area and type of pump. The
rate will be calculated in two ways: as number of discrepan-
cies and errors divided by number of infusions observed
and the proportion of infusions that involved at least one
discrepancy or error; 95% CI will also be provided.
Following the approach established by Husch et al,10 we will
not perform more complex multivariate analyses but will
compare different clinical contexts and different factors in
intravenous medication administration—for example, crit-
ical care versus other wards, and use of smart pumps versus
traditional ones. The aim will be to use the quantitative
analysis as a basis for better understanding contributing
causal factors, through subsequent focus groups, interviews
and in-depth observations. An international comparison
with the US data will also be carried out.
Contextual interviews
We will follow an inductive approach using thematic ana-
lysis.24 25 Codes will be identiﬁed in the transcripts,
broader themes will be recognised from these codes and
codes may be related to each other through hierarchies
and network diagrams. NVivo (QSR International, V.10)
data analysis software will be used to facilitate analysis by
multiple researchers. Interviews and analysis will be
iterative so that subsequent interviews can take advan-
tage of what is learnt from earlier interviews. Relevant
theory will be used to inform additional deductive ana-
lysis if it provides leverage to interpret the data and
explore the ﬁndings more deeply.26
ETHICS AND DISSEMINATION
Ethical considerations
This study has been approved by an NHS Research
Ethics Committee (14/SC/0290) and site-speciﬁc R&D
approval will be sought from each participating trust.
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Data protection, informed consent and addressing observed
errors
At a local level, the point prevalence study is comparable
to an audit of intravenous medication practice for each
site. Written informed consent will be sought from ward
managers by the local co-ordinator before including
ward areas in the study. Patients and ward staff will be
offered an information sheet outlining the study.
Feedback from a patient and public involvement work-
shop has been incorporated into the patient information
sheet and the training of data collectors in how to
approach and inform patients and their visitors about
the study. As per the protocol approved by the ethics
committee, written consent will not be required from
individual patients or ward staff, and ward staff will not
be notiﬁed of the timing of data gathering, to minimise
Figure 1 ECLIPSE patient observation form. ECLIPSE, Exploring the Current Landscape of Intravenous Infusion Practices and
Errors.
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the likelihood of this inﬂuencing their behaviour.
Results from individual sites will be kept secure and
anonymous to other sites.
Written informed consent will be sought from staff
taking part in the qualitative interviews. Interviews will
be audio-recorded and stored on secure password-
protected computers before leaving the site. Interviews
will be transcribed by a professional transcribing service,
with due attention to conﬁdentiality, and the transcripts
anonymised.
If an error with potential to cause harm is identiﬁed
during the point prevalence study, the local data collec-
tors will inform the relevant nursing staff caring for the
patient in a discreet manner so that remedial action can
be taken in line with local procedures.
Dissemination
This study will generate insights into current practice
and the prevalence, causes and clinical importance of
medication administration errors and other procedural
and documentation discrepancies concerning
intravenous infusions, which we anticipate will be of
interest to and have implications for a variety of stake-
holders. Dissemination will take place throughout the
project.
The most immediate beneﬁciaries of our research will
be the patients and staff of participating hospitals. To
achieve rapid local impact, we will discuss ﬁndings with
key staff in each hospital and deliver a tailored written
report relating to each individual site, which participat-
ing trusts will be able to use to inform local policy, train-
ing and procurement.
We will also liaise with relevant national and inter-
national groups, such as NHS England, NAMDET, the
Medusa IV Medicines Guide27 and the Infusion Systems
Safety Initiative, hosted by the Association for the
Advancement of Medical Instrumentation, to aid further
dissemination and translation of the implications of our
ﬁndings into practice. In later phases of the project, we
will also hold workshops with healthcare professionals,
manufacturers and other stakeholders to share our ﬁnd-
ings and reﬁne our recommendations. We aim to inﬂu-
ence the international academic community, as well as
practising clinicians, through conference presentations
and peer-reviewed publications.
Table 3 NCC MERP index for categorising medication
errors23
Harm Category Description
No error A Circumstances or events that have
the capacity to cause error
Error, no
harm
B An error occurred but did not reach
the patient
C An error occurred that reached the
patient but did not cause patient
harm
D An error occurred that reached the
patient and required monitoring to
confirm that it resulted in no harm
to the patient and/or required
intervention to preclude patient
harm
Error,
harm
E An error occurred that may have
contributed to or resulted in
temporary harm to the patient and
required intervention
F An error occurred that may have
contributed to or resulted in
temporary harm to the patient and
required initial or prolonged
hospitalisation
G An error occurred that may have
contributed to permanent harm to
the patient
H An error occurred that required
intervention necessary to sustain
patient life
Error,
death
I An error occurred that may have
contributed to or resulted in the
patient’s death
NCC MERP, National Coordinating Council for Medication Error
Reporting and Prevention.
Table 4 Adapted NCC MERP index that will be used in
the ECLIPSE study
Harm Category Description
No error A1 Discrepancy but no error
A2 Capacity to cause error
Error, no
harm
B An error occurred but is unlikely to
reach the patient
C An error occurred but is unlikely to
cause harm despite reaching the
patient
D An error occurred that would be
likely to have required increased
monitoring and/or intervention to
preclude harm
Error,
harm
E An error occurred that would be
likely to have caused temporary
harm
F An error occurred that would be
likely to have caused temporary
harm and prolonged
hospitalisation
G An error occurred that would be
likely to have contributed to or
resulted in permanent harm
H An error occurred that would be
likely to have required intervention
to sustain life
Error,
death
I An error occurred that would be
likely to have contributed to or
resulted in the patient’s death
ECLIPSE, Exploring the Current Landscape of Intravenous
Infusion Practices and Errors; NCC MERP, National Coordinating
Council for Medication Error Reporting and Prevention.
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Finally, besides disseminating our ﬁndings through
published documents and professional domains, we will
engage with the broader public through social media
channels such as blogs, Twitter and YouTube. We will
develop patient-facing summaries of our results and
recommendations and take advice from patient repre-
sentatives through planned patient and public involve-
ment workshops on other means of sharing ﬁndings
with the public.
RESULTS: PILOT AND INITIAL SITE
Two of the authors have trialled the data collection form
and REDCap Data Entry at their hospital. This provided
an opportunity for practical learning. For example, to
speed data entry, we streamlined the data entry tool and
now advise observers to enter data in parallel, side by
side, so they are able to discuss error classiﬁcation
together in an efﬁcient manner. To help ensure consist-
ency across sites, a document giving examples of errors
and discrepancies, and suggested ratings of likely harm,
will be updated and circulated to data collectors as the
study progresses. Anonymised pilot data will be shown to
participating sites as an example of what to expect in
terms of data collection and data entry.
Learning from the initial participating site has also led
to minor modiﬁcations to training materials and data
collection procedures. For example, we have created a
‘Hints, Tips and Frequently Asked Questions’ sheet for
local data collectors to share knowledge between sites,
which will be updated and circulated as the study pro-
gresses. Data collectors at the ﬁrst site shared inform-
ative short qualitative accounts of many discrepancies
with the study team via email to give the observed errors
and discrepancies appropriate context. This has now
been formally incorporated into the data collection tool.
STUDY STATUS
Point prevalence data collection is ongoing. Data ana-
lysis and interviews will follow.
DISCUSSION
We have described a mixed-methods study comprising
observation and interview in which we aim to determine
the frequency and types of errors that occur in the infu-
sion of intravenous medication, and to explore the range
of infusion practices and the contexts in which errors
occur. The point prevalence methodology described has
a number of inherent limitations. First, the study focuses
on medication administration, and the clinical appropri-
ateness of the intravenous medication prescribed is not
assessed. Data collection will capture infusions at one
point in time and it is unlikely that errors in the prepar-
ation of a drug will be picked up. The hospitals taking
part in this study are not randomly selected, and it is pos-
sible that they may differ in some way from hospitals that
have not been approached or have chosen not to take
part. In addition, as different observers at each participat-
ing hospital collect data, there may be variability between
sites. Observers could make data entry errors. Arguably,
transcription errors are less likely where they are entered
directly into REDCap as it reduces the data entry steps;
however, data can be checked against paper forms where
they are used. To reduce the risk of errors in transcribing,
we advise data collectors to enter the data soon after gath-
ering it so that the observations are still fresh in their
minds. We also advise data collectors to enter the data
together to reduce the likelihood of error. Entering the
data subsequently also allows additional time for reﬂec-
tion and discussion regarding the likely severity of errors,
which may not be possible at the patient’s bedside.
Adapting a protocol used in a US study will facilitate an
international comparison. However, we are aware that cul-
tural differences will need to be considered when compar-
ing data from different countries.12 28 Our study also has
some differences in focus in that we are sampling different
intravenous infusion practices such as gravity feed, non-
smart pumps and smart pumps, rather than focusing
solely on smart pumps, and a wide range of hospitals. We
are also adding a focus on developing an explanation for
the prevalence of error related to different intravenous
practices from a human factors perspective.
We have experienced difﬁculties recruiting English hos-
pitals that use smart pump technologies outside critical
care. This is not surprising given Iacovides et al’s9 UK study
in which less than 40% of their respondents use dose
error reduction software in any clinical areas, and only a
small proportion of these use it outside of critical care. At
least three of our recruited sites have expressed an interest
in doing a pre-smart and post-smart pump implementa-
tion study, using the same data collection methods, since
they anticipate introducing smart pump technology across
their site in the near future. This could lead to extensions
to this protocol and modiﬁcation to the phases described
in table 1. It also indicates that this study’s results will be
timely as more English hospitals are considering whether
to introduce smart pump technology. Sites not considering
implementing smart pump technology have also shown
keen interest in learning more about the performance of
their intravenous infusion practices, highlighting the
importance of this area. We anticipate that the ﬁndings
will result in recommendations for future best practice;
depending on the nature of those recommendations, this
may lead to a future study to assess the impact of recom-
mended interventions.
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